伟德BETVlCTOR1946与澳大利亚墨尔本大学及沃尔特和伊丽莎・霍尔医学研究所（The Walter and Eliza Hall Institute，WEHI）

和拉筹伯大学（LaTrobe）国际讲学系列

时间：2017年10月9日―14日

地点: 伟德BETVlCTOR1946A321和A430会议室

Dr Melissa Davis is a computational cancerbiologist, and Laboratory Head at the Walter and Eliza Hall Institute ofMedical Research. She us an expert in the analysis and reconstruction ofmolecular mechanisms of cancer progression and response to therapy. Herbackground is genetics and computational cell biology, and she currently holdsa National Breast Cancer Foundation Fellowship to study molecular mechanisms ofbreast cancer metastasis. Dr Davis and her team work on the analysis of large,heterogeneous datasets from national and international cancer projects and seekto discover patterns in the data that will help to target patient treatment andpersonalise cancer therapy.

Dr Charity Law is a statistical bioinformatician whose work focuses predominantly on gene expression analyses of high-throughput data. The impact of her work is best illustrated by the popularity of voom, a method for RNA-seq gene expression analysis that she developed which has been cited 750 times since its publication in 2014 (Source: Google Scholar). She currently holds the position of senior research officer in the Molecular Medicine Division at Walter and Eliza Hall Institute of Medical Research, Australia. In addition to differential gene expression, her research interests include differential isoform usage, transcript expression, and histone modification analyses.

Dr Ka Yee Fung completed her PhD studies at Monash University, under the mentorship of Prof Paul Hertzog and her postdoctoral studies at The University of Melbourne, under the mentorship of Prof Liz Hartland. Dr Fung is now a Senior Postdoctoral Fellow in the Inflammation Division at the Walter and Eliza Hall Institute of Medical Research. Her primary research interest involves investigation into how the inflammatory response contributes to cancer development and progression, and the Putoczki Lab, where she is based, is working towards understanding how cytokines modulates the immunological response in the tumour microenvironment, which could provide a new therapeutic target for inflammation-associated cancers.

A.Prof Marc Kvansakul After completing an undergraduate degree inBiochemistry at Imperial College London, Marc was awarded a Wellcome TrustPrize Studentship to pursue a PhD with Prof. Erhard Hohenester at ImperialCollege London, investigating collagen-binding proteins in the extracellularmatrix. In 2004 he took up a Leukemia & Lymphoma Society of Americafellowship to work with Prof. Peter Colman at the Walter and Eliza HallInstitute. In 2010, Marc was awarded an NHMRC Career Development Award toestablish the inaugural structural biology laboratory at La Trobe University.Now an ARC Future Fellow, his work has expanded into the role of innateimmunity molecules in anti-microbial defence.

Dr AndrewWebb is head of the recently formed WEHI ProteomicsResearch Laboratory. He has helped to establish the laboratory as an integralcollaborative resource with the specific aim of applying the next-generation ofproteomics to important biological questions relevant to human health. His ownresearch has focused on understanding the mechanisms of ubiquitin andposttranslational modifications during signal transduction. More recently, hehas established a broad computational proteomics program that incorporatesmachine learned classification into the analysis of proteomic datasets, and isusing quantitative proteomics to identify peptide signatures that distinguishdisease patients from all other control patient groups.

Professor David Huang is a laboratory head at the Walter and Eliza Hall Institute (WEHI) of Medical Research in Melbourne, Australia and Professor in the Department of Medical Biology, Melbourne University. He is a medical graduate and trained in Internal Medicine and in Hematology. He has led an independent research program since 2000. His research interests are studying the molecular mechanisms that regulate cell death in mammalian cells, understanding how deregulation of this process can lead to diseases such as cancer and how these can be targeted for improved therapies. His laboratory has made significant contributions to targeting the BCL2-regulated cell survival pathway for treating patients with cancers. One of these is venetoclax (ABT-199) that has been approved by the US FDA for treating patients with high-risk chronic lymphocytic leukemia (CLL). In 2016, the work of the team he led was awarded the 2016 Johnson & Johnson Eureka Prize for Innovation in Medical Research.